Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TRANYLCYPROMINE vs TRASTUZUMAB DERUXTECAN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

TRANYLCYPROMINE vs TRASTUZUMAB DERUXTECAN: Safety Overview

Metric TRANYLCYPROMINE TRASTUZUMAB DERUXTECAN
Total FAERS Reports 386 2,684
Deaths Reported 38 653
Death Rate 9.8% 24.3%
Hospitalizations 132 780
Average Patient Age 54.4 yrs 56.5 yrs
% Female Patients 64.1% 91.9%
FDA Approval Date Apr 17, 2018 N/A
Manufacturer Solco Healthcare US, LLC Daiichi Sankyo Inc.
Route ORAL INTRAVENOUS
Marketing Status Prescription N/A